Serum β2μ levels from the large tumor burden therapeutic study
. | Days after therapy . | . | . | ||
|---|---|---|---|---|---|
. | -1 . | 14 . | 28 . | ||
| Control, μg/mL | 0.348 ± 0.226 | 5.324 ± 2.158 | 7.796 ± 0.866 | ||
| Flavopiridol, μg/mL | 0.477 ± 0.351 | 3.127 ± 1.337*† | 8.955 ± 1.718† | ||
| HAT, μg/mL | 0.528 ± 0.222 | 1.456 ± 1.143†‡ | 5.400 ± 3.455† | ||
| Combination, μg/mL | 0.446 ± 0.202 | 0.054 ± 0.136‡ | 0.380 ± 0.751 | ||
. | Days after therapy . | . | . | ||
|---|---|---|---|---|---|
. | -1 . | 14 . | 28 . | ||
| Control, μg/mL | 0.348 ± 0.226 | 5.324 ± 2.158 | 7.796 ± 0.866 | ||
| Flavopiridol, μg/mL | 0.477 ± 0.351 | 3.127 ± 1.337*† | 8.955 ± 1.718† | ||
| HAT, μg/mL | 0.528 ± 0.222 | 1.456 ± 1.143†‡ | 5.400 ± 3.455† | ||
| Combination, μg/mL | 0.446 ± 0.202 | 0.054 ± 0.136‡ | 0.380 ± 0.751 | ||
Mice in the control group received 200 μL PBS weekly for 4 weeks. Mice in flavopiridol group received flavopiridol at a dose of 2.5 mg/kg body weight daily for 5 days. Mice in the HAT group received 100 μg HAT weekly for 4 weeks. Mice in the combination group received both flavopiridol and HAT. Data represent mean ± SD.
P < .01 compared with the control group
P < .0001 compared with the combination group
P < .0001 compared with the control group